Prodrug of an ice inhibitor

Details Prodrug of an ice inhibitor Prodrug of an ice inhibitor

2001-05-18

2008-08-26

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S018700, C530S331000, C549S200000, C549S263000

Reexamination Certificate

active

07417029

ABSTRACT:
This invention describes an ICE inhibitor prodrug (I) having good bioavailabilityCompound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.

REFERENCES:
patent: 4465679 (1984-08-01), Huang et al.
patent: 5008245 (1991-04-01), Digenis et al.
patent: 5055451 (1991-10-01), Krantz et al.
patent: 5158936 (1992-10-01), Krantz et al.
patent: 5411985 (1995-05-01), Bills et al.
patent: 5416013 (1995-05-01), Black et al.
patent: 5430128 (1995-07-01), Chapman et al.
patent: 5434248 (1995-07-01), Chapman et al.
patent: 5462939 (1995-10-01), Dolle et al.
patent: 5463124 (1995-10-01), Jacobi et al.
patent: 5486623 (1996-01-01), Zimmerman et al.
patent: 5498616 (1996-03-01), Mallamo et al.
patent: 5498695 (1996-03-01), Daumy et al.
patent: 5519113 (1996-05-01), Jendralla et al.
patent: 5552400 (1996-09-01), Dolle et al.
patent: 5565430 (1996-10-01), Dolle et al.
patent: 5585357 (1996-12-01), Dolle et al.
patent: 5585486 (1996-12-01), Dolle et al.
patent: 5639745 (1997-06-01), Dolle et al.
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5670494 (1997-09-01), Dolle et al.
patent: 5710153 (1998-01-01), Ohmoto et al.
patent: 5716929 (1998-02-01), Bemis et al.
patent: 5756466 (1998-05-01), Bemis et al.
patent: 5847135 (1998-12-01), Bemis et al.
patent: 5869519 (1999-02-01), Karanewsky et al.
patent: 5874424 (1999-02-01), Batchelor et al.
patent: 5877197 (1999-03-01), Karanewsky et al.
patent: 5973111 (1999-10-01), Bemis et al.
patent: 6136834 (2000-10-01), Ohmoto et al.
patent: 6376484 (2002-04-01), Ohmoto et al.
patent: 6531474 (2003-03-01), Wannamaker et al.
patent: 2002/0013278 (2002-01-01), Wannamaker et al.
patent: 0135349 (1985-03-01), None
patent: 0410411 (1991-01-01), None
patent: 0417721 (1991-03-01), None
patent: 0519748 (1992-12-01), None
patent: 0525420 (1993-02-01), None
patent: 0528487 (1993-02-01), None
patent: 0529713 (1993-03-01), None
patent: 0533226 (1993-03-01), None
patent: 0533350 (1993-03-01), None
patent: 0547699 (1993-06-01), None
patent: 0618223 (1994-10-01), None
patent: 0623592 (1994-11-01), None
patent: 0623606 (1994-11-01), None
patent: 0644197 (1995-03-01), None
patent: 0644198 (1995-03-01), None
patent: 0810221 (1997-03-01), None
patent: 93/05071 (1991-03-01), None
patent: 91/15577 (1991-10-01), None
patent: 93/09135 (1993-05-01), None
patent: WO 93/09135 (1993-05-01), None
patent: 93/14777 (1993-08-01), None
patent: 93/16710 (1993-09-01), None
patent: 94/00154 (1994-01-01), None
patent: 94/03480 (1994-02-01), None
patent: 95/00160 (1995-01-01), None
patent: 95/05192 (1995-02-01), None
patent: 95/26958 (1995-10-01), None
patent: 95/29672 (1995-11-01), None
patent: 95/31535 (1995-11-01), None
patent: 95/35308 (1995-12-01), None
patent: 95/35367 (1995-12-01), None
patent: WO 95/35308 (1995-12-01), None
patent: 96/03982 (1996-02-01), None
patent: 96/30395 (1996-10-01), None
patent: 96/33209 (1996-10-01), None
patent: 96/40647 (1996-12-01), None
patent: 97/07805 (1997-03-01), None
patent: 97/08174 (1997-03-01), None
patent: 97/22619 (1997-06-01), None
patent: 98/10778 (1998-03-01), None
patent: 98/11109 (1998-03-01), None
patent: 98/11129 (1998-03-01), None
patent: 98/49189 (1998-11-01), None
patent: WO99/47545 (1999-09-01), None
Kanegane Hirokazu (Pediatric nephrology (Berlin, Germany) 18 (5) 454-6, 2003).
Strasser A. (Annals of the New York Academy of Sciences 917, 541-8, 2000).
Van Den Brande, Jan M. H. ( Annals of the New York Academy of Sciences 973 166-80, 2002).
Kacinski B M (Annals of the New York Academy of Sciences 941, 194-9, 2001.
Tsuchiyama Y (Kidney International 58 (5) 1941-52, 2000).
Li X. C. (Current Opinion in Immunology 12 (5) 522-7, 2000).
Bednarski Jeffrey J. (Arthritis and rheumatism 48 (3) 757-66, 2003).
Abstract of Ando, R., WO 98/04539, issued Feb. 1998.
Abstract of Aibe, K., WO 98/01133, issued Jan. 1998.
Abstract of Ohmoto, K., WO 97/24339, issued Jul. 1997.
Abstract of Ando, R., WO 96/25408, issued Aug. 1996.
Karanewsky, et al.,Conformationally Constrained Inhibitors of Caspase-1(Interleukin 1β Converting Enzyme)And of the Human CED-3 Homologue Caspase - 3(CPP32, Apopain) Bioorganic & Medicinal Chemistry Letters 8 (1998) 2757-2762.
Wannamaker et al.; “(S)-1-((S)-2-{[1-(4-Amino-3•chloro-phenyl)-methanoyl]-amino)-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic ax id ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL • 18” JPET;321:509-516 (2007).
Tocci, PubMed Abstract (Vitam. Horm. 53:27-63. 1997.
Simone, Oncology: Introduction, Cecil Textbook o┌ Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Okamoto et al., Peptide Based ICE Inhibitors: Synthesis, Structure Activity Relationships and Crystallographic Study of the ICE-inhibitor Complex, Chem. Pharm. Bull., 47(1), pp. 11-21, Jan. 1999.
Ravizza T, Lucas SM, Balosso S, Bernardino L, Ku G, Noe F, Malva J, Randle JC, Allan S, Vezzani A. Abstract Inactivation of caspase-1 in rodent brain: a novel anticonvulsîve strategy. Epilepsia. Jul. 2006;47(7):1160-8.
Stack JH, Beaurnont K, Larsen PD, Straley KS, Henkel GW, Randle JC, Hoffman HM. Free Full Text IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. Aug. 15, 2005;175(4):2630-4.
Thakur, et al., “Caspase-1 Inhibitor Reduces Severity of Pseudomones aeruginosa Keratitis in Mice,” Invest Ophthalmol Vis Sci., 2004; 45:3177-3184.
Uhl et al., “Secretion of Human Monocyte Mature Il-1Beta: Optimization and Inhibition by ICE Inhibitors”, Inflammation Res., 44:S211-S212 (1995).
M.A. Ator and R.E. Dolle, “Interleukin-1Beta Converting Enzyme: Biology and the Chemistry of Inhibitors”, Curr. Pharm. Design, 1 pp. 191-210 (1995).
K. Chapman, “Synthesis of a Potent, Reversible Inhibitor of Interleukin-1Beta Converting Enzyme”, Bioorg. Med. Chem. Lett., 2:613-618 (1992).
Dolle et al., “Aspartyl alpha-((Diphenylphosphinyl)oxy) methly Ketones as Novel Inhibitors of Interleukin-1Beta Converting Enzyme. Utility of the Diphenylphosphinic Acid Leaving Group for the Inhibition of Cystein Proteases”, J. Med. Chem., 38:220-222 (1995).
Dolle et al., Aspartyl alpha-((1-Phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl Ketones as Interleukin-1Beta Converting Enzyme Inhibitors. Significance of the P1 and P3 Amido Nitrogens for Enzyme-Peptide Inhibitor Binding:, J. Med. Chem., 37:3863-3866 (1994).
Dolle et al., “P1 Aspartate-Based Peptide alpha-((2,6-Dichlorobenzoyl)oxy)methyl Ketones as Potent Time-Dependent Inhibitors of Interleukin-1Beta-Converting Enzyme”, J. Med. Chem., 37:563-564 (1994).
Edwards et al., “Design, Synthesis and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl alpha-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole”, J. Am. Chem. Soc., 114:1854-1863 (1992).
Elford et al., Reduction of Inflammation of Pyrexia in the Rat by Oral Administration of SDZ 224-015, an Inhibitor of the Interleukin-1 Beta Converting Enzyme, Br. J. Pharmacology, 115:601-606 (1995).
Fan et al., “Stimulation of Angiogenesis by Substance P and Interleukin-1 in the Rat and Its Inhibition by NK1 or Interleukin-1 Receptor Antagonist

Affiliated with

Also associated with

Rating

Prodrug of an ice inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrug of an ice inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrug of an ice inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4007014